Literature DB >> 3149633

In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid.

C S Wong1, G S Palmer, M H Cynamon.   

Abstract

The in-vitro susceptibility of Mycobacterium tuberculosis, M. bovis, and M. kansasii to amoxycillin alone and in combination with 2 mg/l of clavulanic acid was evaluated by broth dilution. The MIC90 of amoxycillin plus clavulanic acid was 4 mg/l compared with greater than 32 mg/l for amoxycillin alone when tested against M. tuberculosis (n = 27). M. bovis (n = 8) was the most susceptible species with an MIC90 of amoxycillin 8 mg/l, compared with 0.5 mg/l for the combination. M. kansasii (n = 6), with an MIC90 of 16 mg/l for amoxycillin plus clavulanic acid was more resistant than either M. tuberculosis or M. bovis. Ticarcillin plus clavulanic acid with an MIC90 of 32 mg/l was less active against M. tuberculosis (n = 28) than amoxycillin plus clavulanic acid. The addition of clavulanic acid to amoxycillin greatly improves its in-vitro activity against M. tuberculosis and M. bovis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149633     DOI: 10.1093/jac/22.6.863

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Altered permeability and beta-lactam resistance in a mutant of Mycobacterium smegmatis.

Authors:  S Mukhopadhyay; P Chakrabarti
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis.

Authors:  Sanjib Bhakta; Joyoti Basu
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

4.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Biochemical characterization of the 49 kDa penicillin-binding protein of Mycobacterium smegmatis.

Authors:  T Mukherjee; D Basu; S Mahapatra; C Goffin; J van Beeumen; J Basu
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

6.  Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Authors:  C J Hackbarth; I Unsal; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.

Authors:  M H Cynamon; Y Zhang; T Harpster; S Cheng; M S DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 8.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

9.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

Authors:  H F Chambers; D Moreau; D Yajko; C Miick; C Wagner; C Hackbarth; S Kocagöz; E Rosenberg; W K Hadley; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.